fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Leqembi (lecanemab) authorized for early alzheimer’s disease in Great Britain – Eisai + Biogen

Written by | 31 Aug 2024

Eisai Co., Ltd. and Biogen Inc. announced that the humanized amyloid-beta (Abeta monoclonal antibody “Leqembi” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the… read more.

Few UK people likely to be suitable for new Alzheimer’s drugs when they come on stream

Written by | 13 Jun 2024

Few people in the UK with early stage Alzheimer’s disease are likely to be suitable for the latest drugs which aim to halt progress of the condition, yet… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.